Precipio (PRPO) Stock Price, News & Analysis

Company Overview

Precipio, Inc. is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput. This platform is complemented by a suite of proprietary reagents and staining kits specifically engineered for hematopathology applications. In addition, Precipio provides specialized molecular assays—including cytogenetics, flow cytometry panels and next-generation sequencing tests—that enable comprehensive profiling of genetic and phenotypic markers in patient samples.

Precipio operates through two primary divisions: a laboratory services arm that performs diagnostic testing on patient specimens using its proprietary technologies, and a product division that markets instruments, reagents and software to hospitals, commercial laboratories and academic research centers. Headquartered in Pittsburgh, Pennsylvania, the company has established strategic partnerships and distribution channels within the United States and is exploring opportunities to expand its presence in select international markets.

Under the leadership of President and CEO Michael Q. McNamara, Precipio has pursued both in-house development and collaborative agreements with academic institutions and industry players to accelerate its product pipeline. Since its founding, the company has remained committed to leveraging innovations in digital pathology and molecular diagnostics, positioning itself as a contributor to the evolving precision medicine paradigm in hematologic oncology.

Key Stats

• Today's Range: $19.48 to $20.07
• 50-Day Range: $12.45 to $21.25
• 52-Week Range: $3.90 to $22.38
• Volume: 30,983 shs
• Average Volume: 12,150 shs
• Market Capitalization: $31.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Precipio Stock Analysis - MarketRank™

Precipio scored higher than 20% of companies evaluated by MarketBeat, and ranked 884th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Precipio.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Precipio is -16.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precipio is -16.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precipio has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently decreased by 80.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precipio does not currently pay a dividend.

Dividend Growth

Precipio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.10% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently decreased by 80.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.45

News Sentiment

Precipio has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Precipio this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for PRPO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Precipio insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.90% of the stock of Precipio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.45% of the stock of Precipio is held by institutions.

PRPO Stock Analysis - Frequently Asked Questions

How have PRPO shares performed this year?

Precipio's stock was trading at $5.54 on January 1st, 2025. Since then, PRPO shares have increased by 252.0% and is now trading at $19.50.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) released its quarterly earnings results on Wednesday, August, 13th. The biotechnology company reported $0.05 EPS for the quarter. The biotechnology company had revenue of $5.65 million for the quarter. Precipio had a negative trailing twelve-month return on equity of 15.00% and a negative net margin of 8.48%.
Read the conference call transcript.

When did Precipio's stock split?

Precipio's stock reverse split before market open on Friday, September 22nd 2023.The 1-20 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Precipio's major shareholders?

Top institutional shareholders of Precipio include AMH Equity Ltd (1.85%). Insiders that own company stock include Richard A Sandberg, Ilan Danieli and Ahmed Zaki Sabet.
View institutional ownership trends.

How do I buy shares of Precipio?

Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Precipio investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:PRPO
• CIK: 1043961
• Web: www.precipiodx.com
• Phone: (203) 787-7888
• Fax: 402-452-5401
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.29 million
• Net Margins: -8.48%
• Pretax Margin: -8.48%
• Return on Equity: -15.00%
• Return on Assets: -10.21%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 0.93
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $21.24 million
• Price / Sales: 1.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.16 per share
• Price / Book: 2.41

Miscellaneous

• Outstanding Shares: 1,620,000
• Free Float: 1,346,000
• Market Cap: $31.87 million
• Optionable: No Data
• Beta: 1.09